Davide Melisi, Associate Professor of Medical Oncology at University of Verona, shared a post on LinkedIn:

“I am honored to have written the editorial for this seminal study on the application of artificial intelligence-based approaches to predict sensitivity to chemotherapeutic treatments in pancreatic cancer. The potential impact of these findings on the future of cancer treatment is immense, and I am proud to have played a part in sharing this important work with the scientific community.
Congratulations to Nelson Dusetti and his colleagues for their outstanding research and these remarkable results.”

Circumventing human limits in precision oncology: AI-enhanced tailoring of post-operative treatment for pancreatic ductal adenocarcinoma

Authors: S. Casalino, C. Zecchetto , V. Merz , A. Quinzii , S. Pietrobono , D. Melisi

Davide Melisi: Predicting sensitivity to chemotherapeutic treatments in pancreatic cancer with AI

Nelson Dusetti reposted Davide Melisi‘s post on LinkedIn, adding:

“We are very grateful to Davide Melisi for the thoughtful editorial and to Annals of Oncology for featuring our work.”

Source: Davide Melisi/LinkedIn and Nelson Dusetti/LinkedIn

Nelson Dusetti is Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.